Eli Lilly agreed to acquire Ventyx Biosciences for roughly $1.2 billion, taking control of a clinical-stage oral NLRP3 inhibitor program that targets inflammatory pathways implicated across cardiometabolic, neurological and autoimmune diseases. The deal was announced by Lilly and reported by multiple outlets; Lilly said the acquisition complements its obesity and inflammation strategy and accelerates an oral immune-drug capability. Lilly offered $14 per share in the transaction, reflecting a notable premium to recent trading. Company executives framed the asset as enabling expansion into oral immunology modalities and as a strategic fit with Lilly’s broader metabolic and neurodegeneration ambitions. The acquisition is likely to reshape competitive positioning in the oral-inflammation space and to draw attention from investors focused on small-molecule immune modulators. Buyout terms and immediate plans include integrating Ventyx’s clinical-stage candidates into Lilly’s development portfolio and pipeline prioritization. Regulators and clinical-readout timelines for the NLRP3 programs will determine near-term R&D focus and potential indications.